Who are Safinamide Methanesulfonate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): rasagiline (Pharmacodynamics).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/safinamide-methanesulfonate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Safinamide Methanesulfonate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safinamide Methanesulfonate (Safinamide Methanesulfonate) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoamine oxidase B (MAO-B) inhibitor. Area: Neurology.

marketed Monoamine oxidase B (MAO-B) inhibitor MAO-B (Monoamine oxidase B) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Safinamide Methanesulfonate (Safinamide Methanesulfonate) — Zambon SpA. Safinamide is a monoamine oxidase B (MAO-B) inhibitor that increases dopamine levels in the brain by blocking the enzyme responsible for dopamine breakdown.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Safinamide Methanesulfonate TARGET	Safinamide Methanesulfonate	Zambon SpA	marketed	Monoamine oxidase B (MAO-B) inhibitor	MAO-B (Monoamine oxidase B)
rasagiline (Pharmacodynamics)	rasagiline (Pharmacodynamics)	University of Maryland, Baltimore	marketed	Monoamine oxidase B (MAO-B) inhibitor	MAO-B (Monoamine oxidase type B)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoamine oxidase B (MAO-B) inhibitor class)

University of Maryland, Baltimore · 1 drug in this class
Zambon SpA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Safinamide Methanesulfonate — Competitive Intelligence Brief. https://druglandscape.com/ci/safinamide-methanesulfonate. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab